ReviewBioengineered
Bacterial proteins and peptides in cancer therapy: today and tomorrow.
Review in Bioengineered. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- A novel soil Bacillus strain GB_SG_008: isolation, characterization, and anticancer potential of an intracellular protein fraction inducing apoptosis and modulating cancer marker proteins.Archives of microbiology · 2025Article
- Combination of magnetic hyperthermia and gene therapy for breast cancer.Apoptosis : an international journal on programmed cell death · 2025Article
- Mannose: A Promising Player in Clinical and Biomedical Applications.Current drug delivery · 2024Review
- Fundamental concepts of protein therapeutics and spacing in oncology: an updated comprehensive review.Medical oncology (Northwood, London, England) · 2023Review
- Fatostatin induces ferroptosis through inhibition of the AKT/mTORC1/GPX4 signaling pathway in glioblastoma.Cell death & disease · 2023Article
- Identification of a cytotoxic factor from a non-pigmented entomopathogenic Serratia marcescens isolate toxic towards human carcinoma cell lines.Archives of microbiology · 2023Article
- Article
- The Azurin-Derived Peptide CT-p19LC Exhibits Membrane-Active Properties and Induces Cancer Cell Death.Biomedicines · 2021Article
- Article
- Anticancer Actions of Azurin and Its Derived Peptide p28.The protein journal · 2020Review
- Colicin N Mediates Apoptosis and Suppresses Integrin-Modulated Survival in Human Lung Cancer Cells.Molecules (Basel, Switzerland) · 2020Article
- Efficient Photodynamic Therapy of Prostate Cancer Cells through an Improved Targeting of the Cation-Independent Mannose 6-Phosphate Receptor.International journal of molecular sciences · 2019Article
- Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells.Molecular biology reports · 2019Article
- Bacterial Proteinaceous Compounds With Multiple Activities Toward Cancers and Microbial Infection.Frontiers in microbiology · 2019Review
- Article
- Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy.Protein science : a publication of the Protein Society · 2017Review
- Bacterial Carriers for Glioblastoma Therapy.Molecular therapy oncolytics · 2017Article
- Discovery of Azurin-Like Anticancer Bacteriocins from Human Gut Microbiome through Homology Modeling and Molecular Docking against the Tumor Suppressor p53.BioMed research international · 2016Article
- Structural studies on Laz, a promiscuous anticancer Neisserial protein.Bioengineered · 2015Article
- Microfluidic chips with multi-junctions: an advanced tool in recovering proteins from inclusion bodies.Bioengineered · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the most deadly diseases worldwide. In the last three decades many efforts have been made focused on understanding how cancer grows and responds to drugs. The dominant drug-development paradigm has been the "one drug, one target." Based on that, the two main targeted therapies developed to combat cancer include the use of tyrosine kinase inhibitors and monoclonal antibodies. Development of drug resistance and side effects represent the major limiting factors for their use in cancer treatment. Nowadays, a new paradigm for cancer drug discovery is emerging wherein multi-targeted approaches gain ground in cancer therapy. Therefore, to overcome resistance to therapy, it is clear that a new generation of drugs is urgently needed. Here, regarding the concept of multi-targeted therapy, we discuss the challenges of using bacterial proteins and peptides as a new generation of effective anti-cancer drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.